Can-fite Biopharma vs Cervomed
Cervomed is the larger business, with $4.0m of revenue in fiscal 2025 against $405,000 for Can-fite Biopharma (9.9 times as much). Can-fite Biopharma grew faster (-39.9% against -58.9%). Cervomed kept more of each dollar of sales as profit: a net margin of -673.1% against -2426.7%.
| Latest fiscal year | Can-fite BiopharmaCANF, 2025 | CervomedCRVO, 2025 |
|---|---|---|
| Revenue | $405,000 | $4.0m |
| Revenue growth | -39.9% | -58.9% |
| Net income | −$9.8m | −$27.0m |
| Operating margin | — | -706.2% |
| Net margin | -2426.7% | -673.1% |
| Return on equity | -178.2% | -93.9% |
| Free cash flow | −$9.0m | −$23.4m |
| Cash | $5.5m | $8.2m |
| Total debt | $0 | $0 |
| Debt to equity | — | 0.0% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | — | 15 |
| Market value | $2.1m | $21.0m |
| Price vs our value range | — | — |
| Moat score | — | — |
| Insider trades, 12 months | 0 buys, 0 sales | 19 buys, 0 sales |